Leqembi’s benefits continue to improve with longer use, study finds
By
Kristen Fischer
Jul 31, 2024
People with early-stage Alzheimer’s disease who take Leqembi can experience more benefits if they stay on it for three years, a new study shows.
Blood test shows promise for detecting Alzheimer’s disease
By
Donna Shryer
Jul 29, 2024
A blood test demonstrated high accuracy for detecting Alzheimer’s disease among people with cognitive symptoms, according to a study presented at the Alzheimer’s Association International Conference...
Study: Having two copies of gene mutation linked to Alzheimer’s may cause onset
By
Kristen Fischer
May 07, 2024
A new study finds that possessing two copies of a specific gene mutation that’s common in Alzheimer’s disease may be the cause behind the disease in those people.
Study: ‘Cognitive frailty’ may be result of aging — not the brain changes found in dementia
By
Alicia Lasek
Jan 11, 2022
Reduced cognitive function without substantial memory complaints may be a normal part of aging and not an early sign of Alzheimer’s disease or other dementias, investigators say.
Generic for Viagra holds promise as Alzheimer’s disease treatment, Cleveland Clinic researchers say
Dec 08, 2021
Users of sildenafil are 69% less likely to develop Alzheimer’s disease than their peers who do not use the drug, investigators report. A clinical trial to confirm its benefits for Alzheimer’s patients...
Scientists say they’ve zeroed in on a cause of Alzheimer’s
By
Alicia Lasek
Dec 03, 2021
Researchers from the University of California, Riverside say they have uncovered a reason why some people with plaques and tangles in their brains do not develop Alzheimer’s disease.
NIH highlights decade of Alzheimer’s advancements tied to small business investments
By
Alicia Lasek
Aug 11, 2021
A new paper showcases the results of 11 years of federal investment in dementia research, including advancements in care intervention, diagnostics and therapeutics.
Eli Lilly aims for dementia drug candidate’s approval in 2022; wants to ‘prioritize access’
By
Alicia Lasek
Aug 04, 2021
The Alzheimer’s disease-modifying drug donanemab is on track to be considered for full FDA approval by 2022, its developer said.
FDA approves first drug to slow Alzheimer’s in controversial decision
By
Alicia Lasek
Jun 07, 2021
The evidence convincingly shows that aducanumab (Aduhelm) removes beta amyloid — a hallmark of Alzheimer’s — from the brain, slowing the disease’s progression and giving patients and families much-needed...
Clinical briefs for Friday, March 26
By
Alicia Lasek
Mar 26, 2021
California and Florida prepare to open vaccine access to all adults … Common Alzheimer’s treatment linked to slower cognitive decline …Flu shot associated with fewer, less severe COVID cases...